In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qiagen Buys Molecular Staging: Stalking PCR

Executive Summary

Although scientific and clinical interest in molecular diagnostics is at an all-time high, companies are still struggling to find the right business model for the field. Qiagen's recent acquisition of the assets of Molecular Staging, one of the sector's pioneers, reflects the promise and limitations of a field in which competition is fierce, development time is lengthy, and technology is evolving much faster than general market acceptance.

You may also be interested in...



A Genomics Tool Company's Transition From Research to the Clinic

The late 1990s genomics implosion spurred many genomics tools companies focusing on research laboratories to re-direct their attention to the clinic. The expectation was that innovative diagnostic tests and analytic platforms could do for them what collapsing research markets couldn't. Among those hit hard was Third Wave Technologies Inc., which was forced to re-evaluate its priorities and step up the pace of its commercialization timetable, while reducing emphasis on research. TWT's struggles are similar to those of other genomics companies facing the same tough environment, but its story is also universally applicable to medical device startups, which start with a strong scientific orientation and, often painfully, need to make business their major priority.

Molecular Staging Inc.

Founded in November 1996, Molecular Staging is developing diagnostic technologies licensed from the Yale University School of Medicine.

Qiagen's Coup in DNA Sample Prep

Qiagen's success in exploiting an overlooked niche in research diagnostics--sample prep for nucleic acid tests--has driven an extraordinary growth story. But its performance has attracted the attention of big diagnostics companies. As it looks to expand into clinical markets, it faces levels of competition it's never seen before.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel